Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone

Background. The relationship between diabetes and periodontitis is bidirectional, and there is now consensus that periodontitis and diabetes are comorbid. There is a quest for a drug that can be used to treat both conditions simultaneously. This study evaluated the anti-inflammatory and osteoprotect...

Full description

Saved in:
Bibliographic Details
Main Authors: Man Yang, Yunqing Pang, Minyu Pei, Yuanyuan Li, Xuemin Yuan, Rongbing Tang, Jing Wang
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2022/8260111
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832558322107023360
author Man Yang
Yunqing Pang
Minyu Pei
Yuanyuan Li
Xuemin Yuan
Rongbing Tang
Jing Wang
author_facet Man Yang
Yunqing Pang
Minyu Pei
Yuanyuan Li
Xuemin Yuan
Rongbing Tang
Jing Wang
author_sort Man Yang
collection DOAJ
description Background. The relationship between diabetes and periodontitis is bidirectional, and there is now consensus that periodontitis and diabetes are comorbid. There is a quest for a drug that can be used to treat both conditions simultaneously. This study evaluated the anti-inflammatory and osteoprotective effects of liraglutide (LIRA) on periodontitis in diabetic rats. Methods. Male Wistar rats (n=46) were randomly divided into four groups: control group (n=8), LIRA group (n=8), diabetes-associated periodontitis+0.9% saline group (diabetic periodontitis (DP)+NaCl group, n=15), and diabetes-associated periodontitis+LIRA group (DP+LIRA group, n=15). LIRA treatment lasted for 4 weeks (300 μg/kg/d) after establishment of a rat model of DP. The expression of IL-6, TNF-α, and IL-1β was detected by enzyme-linked immunosorbent assay. The morphological changes of periodontal tissues were observed by hematoxylin–eosin staining. The absorption of alveolar bone and its ultrastructural changes were observed by histomorphometry and microcomputed tomography. The expression of receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) in alveolar bone was detected by immunohistochemistry. The levels of Runx2 mRNA and ALP mRNA in the gingival epithelium were examined by quantitative real-time polymerase chain reaction. Results. LIRA decreased alveolar bone resorption, improved the microstructure of alveolar bone, and reduced periodontal inflammation and damage (P<0.05). LIRA also reduced blood glucose level and inhibited the secretion of serum IL-6, TNF-α, and IL-1β (P<0.05). In addition, after treatment with LIRA, the ratio of RANKL/OPG was reduced, and the expression levels of ALP mRNA and Runx2 mRNA were upregulated (P<0.05). Conclusions. LIRA not only controls blood glucose level but also reduces inflammation and bone loss and enhances osteogenic differentiation in diabetes-associated periodontitis. Those indicate that LIRA may be used as a potential medicine for the adjunctive therapy of diabetes-periodontitis comorbidity.
format Article
id doaj-art-717f42ad98cf4111be90affdacbcc58f
institution Kabale University
issn 2314-6753
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-717f42ad98cf4111be90affdacbcc58f2025-02-03T01:32:36ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/8260111Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One StoneMan Yang0Yunqing Pang1Minyu Pei2Yuanyuan Li3Xuemin Yuan4Rongbing Tang5Jing Wang6School/Hospital of StomatologySchool/Hospital of StomatologySchool/Hospital of StomatologySchool/Hospital of StomatologySchool/Hospital of StomatologySchool/Hospital of StomatologySchool/Hospital of StomatologyBackground. The relationship between diabetes and periodontitis is bidirectional, and there is now consensus that periodontitis and diabetes are comorbid. There is a quest for a drug that can be used to treat both conditions simultaneously. This study evaluated the anti-inflammatory and osteoprotective effects of liraglutide (LIRA) on periodontitis in diabetic rats. Methods. Male Wistar rats (n=46) were randomly divided into four groups: control group (n=8), LIRA group (n=8), diabetes-associated periodontitis+0.9% saline group (diabetic periodontitis (DP)+NaCl group, n=15), and diabetes-associated periodontitis+LIRA group (DP+LIRA group, n=15). LIRA treatment lasted for 4 weeks (300 μg/kg/d) after establishment of a rat model of DP. The expression of IL-6, TNF-α, and IL-1β was detected by enzyme-linked immunosorbent assay. The morphological changes of periodontal tissues were observed by hematoxylin–eosin staining. The absorption of alveolar bone and its ultrastructural changes were observed by histomorphometry and microcomputed tomography. The expression of receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) in alveolar bone was detected by immunohistochemistry. The levels of Runx2 mRNA and ALP mRNA in the gingival epithelium were examined by quantitative real-time polymerase chain reaction. Results. LIRA decreased alveolar bone resorption, improved the microstructure of alveolar bone, and reduced periodontal inflammation and damage (P<0.05). LIRA also reduced blood glucose level and inhibited the secretion of serum IL-6, TNF-α, and IL-1β (P<0.05). In addition, after treatment with LIRA, the ratio of RANKL/OPG was reduced, and the expression levels of ALP mRNA and Runx2 mRNA were upregulated (P<0.05). Conclusions. LIRA not only controls blood glucose level but also reduces inflammation and bone loss and enhances osteogenic differentiation in diabetes-associated periodontitis. Those indicate that LIRA may be used as a potential medicine for the adjunctive therapy of diabetes-periodontitis comorbidity.http://dx.doi.org/10.1155/2022/8260111
spellingShingle Man Yang
Yunqing Pang
Minyu Pei
Yuanyuan Li
Xuemin Yuan
Rongbing Tang
Jing Wang
Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone
Journal of Diabetes Research
title Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone
title_full Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone
title_fullStr Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone
title_full_unstemmed Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone
title_short Therapeutic Potential of Liraglutide for Diabetes–Periodontitis Comorbidity: Killing Two Birds with One Stone
title_sort therapeutic potential of liraglutide for diabetes periodontitis comorbidity killing two birds with one stone
url http://dx.doi.org/10.1155/2022/8260111
work_keys_str_mv AT manyang therapeuticpotentialofliraglutidefordiabetesperiodontitiscomorbiditykillingtwobirdswithonestone
AT yunqingpang therapeuticpotentialofliraglutidefordiabetesperiodontitiscomorbiditykillingtwobirdswithonestone
AT minyupei therapeuticpotentialofliraglutidefordiabetesperiodontitiscomorbiditykillingtwobirdswithonestone
AT yuanyuanli therapeuticpotentialofliraglutidefordiabetesperiodontitiscomorbiditykillingtwobirdswithonestone
AT xueminyuan therapeuticpotentialofliraglutidefordiabetesperiodontitiscomorbiditykillingtwobirdswithonestone
AT rongbingtang therapeuticpotentialofliraglutidefordiabetesperiodontitiscomorbiditykillingtwobirdswithonestone
AT jingwang therapeuticpotentialofliraglutidefordiabetesperiodontitiscomorbiditykillingtwobirdswithonestone